Relypsa's (RLYP) Veltassa Still in its Early Going - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Mara Goldstein reiterated a Buy rating and $41 price target Relypsa, Inc. (NASDAQ: RLYP) following Veltassa RX ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
